SCHEMBL2420459

SCHEMBL2420459

CCC(O)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 11/20 0.38
PDE2A O00408 1/20 0.37
RECQL P46063 1/20 0.36
LMNA P02545 1/20 0.35
KDR P35968 4/20 0.35
SRC P12931 2/20 0.35
FGFR2 P21802 2/20 0.35
AXL P30530 2/20 0.35
FLT3 P36888 2/20 0.35
MST1R Q04912 2/20 0.35
KIT P10721 1/20 0.35
KCNH2 Q12809 1/20 0.34
INPPL1 O15357 2/20 0.33
AURKA O14965 1/20 0.33
ABL1 P00519 1/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
YES1 P07947 1/20 0.33
EPHA2 P29317 1/20 0.33
LTK P29376 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2422975 0.86 MET (0.36) METKDRSRCFGFR2AXL
SCHEMBL21030286 0.84 LMNA (0.40) PDE2ARECQLLMNAKDRKCNH2
SCHEMBL2422450 0.82 MET (0.39) METKDRSRCFGFR2AXL
SCHEMBL30509670 0.80 MET (0.44) METKDRSRCFGFR2AXL
SCHEMBL1581742 0.80 MET (0.44) METKDRSRCFGFR2AXL
SCHEMBL30005568 0.80 MET (0.44) METKDRSRCFGFR2AXL
SCHEMBL2419732 0.80 MET (0.44) METKDRSRCFGFR2AXL
SCHEMBL30005904 0.80 MET (0.44) METKDRSRCFGFR2AXL
SCHEMBL30236403 0.80 MET (0.44) METKDRSRCFGFR2AXL
SCHEMBL488680 0.80 MET (0.44) METKDRSRCFGFR2AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265616-B1 FURO-AND THIENO[3,2-C]PYRIDINES OSI PHARM INC (US) 2013-11-20 EP disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
WO-2009100282-A1 FURO-AND THIENO[3,2-C] PYRIDINES OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines RET, MET, ERBB2 MET 2/4885PDE2A 2513/4885RECQL 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.